A review of vaccine research and development: human enteric infections

被引:122
作者
Girard, MP
Steele, D
Chaignat, CL
Kieny, MP
机构
[1] Univ Paris 07, UFR Biochem, F-69008 Lyon, France
[2] WHO, CH-1211 Geneva, Switzerland
关键词
vaccines; gastroenteritis; dysentery; cholera; diarrhoeas; typhoid fevers; Traveler's diarrhoea; calicivirus; rotavirus; Campylobacter; Shigella; Salmonella; Vibrio cholerae; enterotoxigenic; Escherichia coli; ETEC;
D O I
10.1016/j.vaccine.2005.10.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Worldwide, enteric infections rank third among all causes of disease burden, being responsible for some 1.7-2.5 million deaths per year, mostly in young children and infants in developing countries. The main infectious agents responsible for human enteric infections include several viruses (enteric adenoviruses, astroviruses, human caliciviruses (HuCV), rotaviruses (RV)) and several bacterial agents, such as Campylobacter jejuni, a variety of pathogenic Escherichia coli strains including enterotoxigenic E. coli (ETEC), several Shigella species, various Salmonella strains including S. typhi and S. paratyphi, the agents of typhoid fever, and Vibrio cholerae, the agent of cholera. While effective vaccines are available at present against typhoid fever and cholera, no vaccine is available against illnesses caused by HuCV, Campylobacter, ETEC or the Shigellae. Rotavirus vaccines have had more success, although RV disease prevention suffered a major setback in 1999 with the withdrawal of a live simian-human reassortant RV vaccine less than a year after its introduction. New live oral RV vaccines have now been developed and are or should presently be ready for licensure. This article reviews the state of the art in vaccine R&D against human viral and bacterial enteric infections of public health importance. (c) 2005 World Health Organization. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:2732 / 2750
页数:19
相关论文
共 158 条
[1]   Epidemiology of enterotoxigenic Escherichia coli diarrhea in a pediatric cohort in a periurban area of lower Egypt [J].
Abu-Elyazeed, R ;
Wierzba, TF ;
Mourad, AS ;
Peruski, LE ;
Kay, BA ;
Rao, M ;
Churilla, AM ;
Bourgeois, AL ;
Mortagy, AK ;
Kamal, SM ;
Savarino, SJ ;
Campbell, JR ;
Murphy, JR ;
Naficy, A ;
Clemens, JD .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (02) :382-389
[2]   Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis [J].
Ali, M ;
Emch, M ;
von Seidlein, L ;
Yunus, M ;
Sack, DA ;
Rao, M ;
Holmgren, J ;
Clemens, JD .
LANCET, 2005, 366 (9479) :44-49
[3]   Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits [J].
Ang, CW ;
Noordzij, PG ;
de Klerk, MA ;
Endtz, HP ;
van Doorn, PA ;
Laman, JD .
INFECTION AND IMMUNITY, 2002, 70 (09) :5081-5085
[4]  
[Anonymous], 2005, Wkly Epidemiol Rec, V80, P94
[5]  
[Anonymous], 2004, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD002848.PUB2
[6]   Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children [J].
Ashkenazi, S ;
Passwell, JH ;
Harlev, E ;
Miron, D ;
Dagan, R ;
Farzan, N ;
Ramon, R ;
Majadly, F ;
Bryla, DA ;
Karpas, AB ;
Robbins, JB ;
Schneerson, R .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) :1565-1568
[7]  
Ashkenazi Shai, 2004, Semin Pediatr Infect Dis, V15, P246, DOI 10.1053/j.spid.2004.07.005
[8]   Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice [J].
Ball, JM ;
Hardy, ME ;
Atmar, RL ;
Conner, ME ;
Estes, MK .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1345-1353
[9]   Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study [J].
Ball, JM ;
Graham, DY ;
Opekun, AR ;
Gilger, MA ;
Guerrero, RA ;
Estes, MK .
GASTROENTEROLOGY, 1999, 117 (01) :40-48
[10]   IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A PROTOTYPE CAMPYLOBACTER KILLED WHOLE-CELL VACCINE IN MICE [J].
BAQAR, S ;
APPLEBEE, LA ;
BOURGEOIS, AL .
INFECTION AND IMMUNITY, 1995, 63 (09) :3731-3735